Insmed retains rights to brensocatib after talks with AstraZeneca end,
Insmed Incorporated, a pharmaceutical company based in Bridgewater, New Jersey, announced today that negotiations with AstraZeneca AB to develop and commercialize brensocatib have ended without an agreement. Discussions following AstraZeneca’s execution of its latest version of the 2016 licensing agreement ended on Wednesday, June 12, 2024, after a negotiation period expired. The licensing agreement, originally […]
Insmed retains rights to brensocatib after talks with AstraZeneca end, Read Post »